<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657602</url>
  </required_header>
  <id_info>
    <org_study_id>9588</org_study_id>
    <nct_id>NCT03657602</nct_id>
  </id_info>
  <brief_title>Immediate Postpartum Insertion of Contraceptive Intrauterine Devices</brief_title>
  <official_title>Immediate Postpartum Insertion of Kyleena vs Mirena Contraceptive Intrauterine Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized trial, investigators intend to determine the expulsion and discontinuation
      rate of immediate postpartum intrauterine devices in the patient population of the University
      of Oklahoma Women's Healthcare Specialists Clinic (OUWHSC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between 40-57% of women report having unprotected intercourse prior to the 6 week postpartum
      visit. Immediate postpartum long-acting reversible contraception (LARC) is extremely
      important in preventing short-interval and unintended pregnancies. The postpartum period is
      an excellent time for intrauterine device (IUD) or implant insertion as women are often
      highly motivated to prevent unwanted pregnancies at this time. Per the American College of
      Obstetrics and Gynecology (ACOG), expulsion rates for immediate postpartum IUD insertion are
      higher than for interval or post-abortion insertion. Despite the higher expulsion rate of
      immediate postpartum IUD placement over interval placement, cost-benefit analysis data
      strongly suggest the superiority of immediate placement in reduction of unintended pregnancy,
      especially for women at greatest risk of not attending the postpartum follow-up visit. This
      study will randomly allocate participants one to one to the Kyleena or the Mirena IUD group,
      and participants will be blinded to allocation of groups. Participants will follow up at
      routine postpartum visit within 4 weeks of delivery, and a second follow up will be performed
      at 10 weeks. Ultimately, this study will attempt to provide more detailed information on the
      difference of rates of expulsion and discontinuation of the different-sized Mirena and
      Kyleena intrauterine devices.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly allocated one to one to the Kyleena or Mirena group and assessment will occur in parallel</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant will be blinded to group assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Expulsion of intrauterine contraception</measure>
    <time_frame>within 10 weeks of placement</time_frame>
    <description>IUD string check and ultrasound check</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of intrauterine contraception</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Date IUD is removed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Contraceptive Kyleena</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Kyleena Intrauterine System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contraceptive Mirena</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Mirena Intrauterine System</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kyleena Intrauterine System</intervention_name>
    <description>Participant will be randomly allocated to this intervention</description>
    <arm_group_label>Contraceptive Kyleena</arm_group_label>
    <other_name>levonorgestrel intrauterine system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirena Intrauterine System</intervention_name>
    <description>Participant will be randomly allocated to this intervention</description>
    <arm_group_label>Contraceptive Mirena</arm_group_label>
    <other_name>levonorgestrel intrauterine system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  desire an intrauterine device as postpartum contraception

          -  want to avoid pregnancy for at least 1 year

          -  are currently pregnant

          -  desire immediate postpartum IUD insertion.

        Exclusion Criteria:

          -  known uterine or cervical anomaly

          -  untreated cervical infection

          -  untreated cervical infection

          -  pelvic infection within 3 months of the study

          -  recent (within last 3 months) or active intrauterine infection

          -  genital bleeding of unknown etiology

          -  history of postpartum or postabortal sepsis

          -  cervical cancer or carcinoma in suit

          -  plan to leave Tulsa area within 10 weeks postpartum

          -  allergy to device ingredients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valorie Owens, MSW</last_name>
    <role>Study Director</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma - Tulsa</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

